KR102045946B1 - Cosmetic composition and external composition comprising acylated saponin for anti-inflammatory - Google Patents

Abstract

The present invention relates to an anti-inflammatory cosmetic composition or an anti-inflammatory skin external preparation containing acylated saponin as an active ingredient.
The anti-inflammatory cosmetic composition or anti-inflammatory skin external preparation according to the present invention shows excellent cyclooxygenase inhibition and inflammation inhibitory effect, and was very excellent in cytotoxicity and skin safety as compared to the existing anti-inflammatory agents.

Description

Anti-inflammatory cosmetic composition or anti-inflammatory skin external preparation containing acylated saponin as an active ingredient {Cosmetic composition and external composition comprising acylated saponin for anti-inflammatory}

The present invention relates to an anti-inflammatory cosmetic composition or an anti-inflammatory skin external preparation comprising acylated saponin as an active ingredient.

Cosmetics are products used to protect the skin and to beautify cleanliness, but if you look closely at the cosmetic composition, ingredients different from the purpose of protecting the skin are used as essential to the formation of the product. Examples include surfactants, preservatives, fragrances, sunscreens, pigments and other ingredients used to impart efficacy and effects. These ingredients are generally known to cause various side effects such as inflammation, rashes and edema in the skin (Maibach, H. I., Contact Dermatitis, 6; (1980) 369-404). In addition, fatty acids, higher alcohols, and proteins in sebum, sweat, or cosmetics that are released from the body may be decomposed into highly toxic substances by skin floras present on the skin, which may cause skin inflammation. . In particular, with the recent development of functional cosmetics, products containing components such as AHA (alpha hydroxy acid), retinol, arbutin, that is, a variety of functional cosmetics having various functions even if the skin has some side effects.

Materials used for anti-inflammatory purposes to date include nonsteroidal flufenamic acid, ibuprofen, benzydamine, indomethacin, and prednisolone as a steroid. Dexamethasone (dexamethasone) and the like, and other allantoin, azene, hydrocortisone, licorice acid and its derivatives (β-glycileic acid, glycylic acid derivatives) are known to be effective in anti-inflammatory (Ministry of Finance, New Cosmetic Science, Namsan Party, p162, 1993). However, steroid-based substances have most problems in terms of safety to the skin, and their usage is limited (Kim Chang-jong, Pathology, Hallym Corp., p61-69, 1988). Indomethacin cannot be used in cosmetics. The derivatives are difficult to stabilize or have poor solubility, which makes it difficult to achieve practical effects due to the concentration limitations in the actual product application.

Accordingly, the present invention not only has an excellent anti-inflammatory effect, but also is safe for the skin and finds a substance easily formulated into a cosmetic composition or an external preparation for skin, and to provide an anti-inflammatory cosmetic composition or an anti-inflammatory skin external preparation including the same.

As a means for solving the above problems, the present invention provides an anti-inflammatory cosmetic composition or an anti-inflammatory skin external preparation comprising an acylated saponin as an active ingredient.

The saponin is a general term for the glycosides of tritelfen and steroids widely distributed in the plant system. Saponin is derived from the Latin sapona (soap) and is a natural surfactant that creates a persistent foam when shaken with water. In the East, saponin has been used as a herbal medicine for decontamination, eukaryotic, anti-inflammatory, cardiac and diuretic. Recently, it is interested in the antioxidant and emulsifying power of saponin and used in cosmetics. Abnormalities are prevented or used as a hair restorer.

On the other hand, the inventors of the present invention are not only excellent in anti-inflammatory effect, but also safe for skin, and easy to formulate into cosmetic compositions or external preparations for skin, while acylated saponin (acylated saponin) has an excellent anti-inflammatory effect and has a specific odor. Was found to be a safe component to the skin and completed the present invention. Through the following examples, the inventors confirmed that the acylated saponin according to the present invention has excellent cyclooxygenase inhibitory effect and anti-inflammatory effect (Examples 1 and 2). In addition, it was confirmed that the skin safety for the human body is very excellent (Examples 3 and 4).

Acylated saponin according to the present invention may be prepared using a commercially available product or separated from plants, semisynthetic or synthesized. The plant may be, but is not limited to, Winter cherries (Withania somnifera), daisies (pellis perennis), bark bark tree (Quillaja Saponaria), albizia adianthifolia, and gleditsia sinensis. In addition, but not limited thereto, for example, the acylated saponin may be cytosinedoside VII, cytosinedoside VIII, velissaponin BA1, bellaissaponin BA2 ( Bellissaponins BA2), acylated triterpenoid saponin, adianthifoliosides A, adianthifoliosides B, gleditsia saponins C, gladicia It may be at least one member selected from the group consisting of gleditsia saponins D and gleditsia saponins E.

Acylated saponins according to the present invention can be prepared using commercially available products or based on known methods. The preparation of acylated saponin can be varied within the scope apparent to those skilled in the art, and the present invention includes the scope thereof.

For example, the present invention may be isolated and purified from the extract of the plant.

The extraction solvent used to extract acylated saponin from plants may be, but is not limited to, a solvent selected from water, organic solvents or mixtures thereof. The organic solvent is a polar solvent such as alcohol having 1 to 5 carbon atoms, ethyl acetate, acetone; Nonpolar solvents such as ether, chloroform, benzene, hexane and dichloromethane; Or a mixed solvent thereof. For example, the alcohol having 1 to 5 carbon atoms may be selected from methanol, ethanol, propanol, butanol or isopropanol and the like.

In addition, the acylated saponin according to the present invention may be a fraction obtained by re-dividing the primary extract extracted using the extracting solvent using an extractant having a different polarity. For example, the solvent with different polarities may be ether, benzene, hexane.

Two or more solvents may be used in the fractionation, and each solvent extract may be prepared using sequentially or mixed according to the polarity of the solvent, but is not limited thereto.

The prepared extract or the fraction obtained by performing the fractionation process can be separated and purified the active ingredient according to the conventional separation and purification method. Although not limited thereto, High Performance Liquid Chromatography (HPLC) may be used.

Acylated saponin prepared by the above method may be in the form of a salt. The salt may be an acid addition salt formed using an organic acid or an inorganic acid, and the organic acid may be, for example, formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid, malic acid, maleic acid, malonic acid, fumaric acid, and the like. , Succinic acid, succinic acid monoamide, glutamic acid, tartaic acid, oxalic acid, citric acid, glycolic acid, glucuronic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, dichloroacetic acid, aminooxy acetic acid, benzenesulfonic acid, p-toluenesulfonic acid and It may be at least one selected from the group consisting of methanesulfonic acid salts. The inorganic acid may be at least one selected from the group consisting of, for example, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid, or boric acid salts. It may preferably be in the form of hydrochloride or acetate, more preferably in the form of hydrochloride.

In addition to the above, salts that can be additionally salted are gabar salt, gabapentin salt, pregabalin salt, nicotinate, adipate salt, hemimalonate, cysteine salt, acetylcysteine salt, methionine salt, arginine salt, lysine salt, ornithine salt or Aspartate.

In the present invention, "inflammation" refers to a phenomenon that occurs when a cell or tissue is damaged by any cause to minimize the response and to restore the damaged site to its original state, and to restore nerves, blood vessels, and lymphatic vessels. It is a collective name for causing humoral reactions and cellular reactions, resulting in pain, edema, redness, and fever. The disease caused by the inflammation may be at least one selected from the group consisting of various dermatitis, allergies, systemic lupus erythematosus, retinitis, gastritis, hepatitis, enteritis, pancreatitis and nephritis, the allergy is anaphylaxis, allergic rhinitis ( allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, atopic dermatitis, contact dermatitis, urticaria, insect allergy, food allergy or drug allergy.

The inflammation is caused by various biochemical phenomena in vivo, and in particular, cyclooxygenase (COX) and L-arginine (L-), enzymes involved in biosynthesis of prostaglandin from arachidonic acid. Nitric oxide synthase (NOS), an enzyme that produces nitric oxide (NO) from arginin, is known to play an important role in mediating the inflammatory response.

In the present invention, the term "prostaglandin (PG)" is a kind of bioactive hormone synthesized in the body, and has a function of regulating the inflammatory response. The prostaglandins are of three types, PG1, PG2 and PG3, PG1 and PG3 inhibit inflammation, and PG2 causes inflammation. The prostaglandins are biosynthesized using cyclooxygenase (Cyclooxygenase, COX) using arachidonic acid as a precursor.

As used herein, the term "cyclocygenase (COX)" is an enzyme that catalyzes the first step of the synthesis of prostaglandins, and introduces two molecules of oxygen into arachidonic acid to synthesize PG2, thereby producing prostaglandin endoperox. Also called seed synthase. Cyclooxygenase (COX) also has two types of isoforms. Cyclooxygenase-1 (COX-1) is always present in cells to provide prostaglandins (PGs) necessary for cytoprotective action. While synthesizing, COX-2 is known to play an important role in the inflammatory response due to a rapid increase in cells during the inflammatory response.

The term "nitric oxide (NO)" in the present invention is generated by iNOS (induced NOS) induced by various cytokines or external stimuli, and is known to cause cytotoxicity or various inflammatory reactions. In addition, chronic inflammation is known to be associated with increased iNOS activity (Appleton L. et al Adv. Phamacol., 35. 27-28.1996).

Acylated saponins according to the present invention have a cyclooxygenase (COX) inhibitory activity, and are particularly effective for inflammation mediated by the biosynthesis of prostaglandins.

The present invention can provide a desirable anti-inflammatory effect when it contains an effective amount of acylated saponin. In the present invention, "effective amount" means an amount capable of exhibiting sufficient cyclooxygenase (COX) inhibitory activity. For example, the effective amount of the acylated saponin may include 0.001 to 20 parts by weight, based on 100 parts by weight of the total composition. For example, it may be 0.001 to 10 parts by weight, 0.01 to 20 parts by weight, 0.01 to 10 parts by weight and 0.1 to 10 parts by weight. This is because when the acylated saponin is included in less than 0.001 parts by weight can not expect a sufficient anti-inflammatory effect, if it contains more than 20 parts by weight may cause unwanted reactions such as allergies or skin safety problems It is to prevent. The composition as described above is not necessarily limited thereto, and may vary depending on the purpose of the composition, the form to be commercialized, and the state of the application target.

On the other hand, the composition of this invention may contain 1 or more types of components which show a well-known anti-inflammatory effect, and a component which enhances an anti-inflammatory effect.

By including additional anti-inflammatory components, the anti-inflammatory effect may be further enhanced. As anti-inflammatory ingredients known in the art, ibuprofen, flufenamic acid and indomethacin on the nonsteroidal side, prednisolone and dexamethasone on the steroid side, other allantoins, azene It may further comprise one or two or more components selected from the group consisting of hydrocortisone, licorice acid and derivatives thereof. The additional anti-inflammatory component includes all the analogs and the like having the same effects as those listed above. In addition, as a known anti-inflammatory component that can be used in cosmetic compositions, hyaluronic acid, Daphnetin, glycyrrhizin, quercetin, rosmarinic acid, madecassic acid , Camazulene, Bicalein, Emodin, Astaxanthin, norbergenin, 4-O-methylhonokiol, Polydatin (polydatin), ferulic acid, 2-methoxycinnamaldehyde, 2,4-dihydroxyacetophenone, terpinen-4-ol (terpinen-4) -ol) one or two or more components selected from the group consisting of panthenol, fruit extract, portulaca extract, alanyl glutamine, beta-glutan and derivatives thereof It may further comprise. The additional anti-inflammatory components may include all of the analogues and plant extracts thereof having the same effect as those listed above.

The added ingredients may be included in 0.0001 to 10 parts by weight with respect to 100 parts by weight of the total composition, the content range according to the requirements of the activity of cyclooxygenase (Cyclooxygenase, COX), skin safety, ease of formulation, etc. It can be adjusted.

The cosmetic composition or the external preparation for skin according to the present invention may be formulated through conventional methods. When formulated as an external preparation for skin, reference may be made to what is disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA, and when formulated as a cosmetic, International cosmetic ingredient dictionary, 6th ed., The cosmetic, Toiletry and Fragrance Reference may be made to the contents disclosed in Association, Inc., Washington, 1995. Such documents are incorporated as part of this specification.

Although not limited thereto, the cosmetic composition may be prepared in the form of a general emulsion formulation and solubilized formulation. For example, lotion, such as a flexible lotion or a nourishing lotion; Latex, such as facial lotion and body lotion; Creams such as nutrition creams, moisture creams and eye creams; essence; Cosmetic ointments; spray; Gels; pack; Sunscreen; Makeup base; Foundations such as liquid type, solid type or spray type; powder; Makeup removers such as cleansing cream, cleansing lotion and cleansing oil; Or a detergent such as a cleansing foam, soap, body wash, or the like. In addition, the external preparation for the skin may have a formulation such as, but not limited to, ointment, patch, gel, cream or spray.

The content of the active ingredient may vary depending on the formulation. For example, the cosmetic composition may include a relatively high concentration of the acylated saponin in the case of a wash-off type cosmetic such as a make-up remover or a detergent, in which an active ingredient stays on the skin within a short period of time. . On the other hand, leave-on type cosmetics such as lotion, emulsion, cream, essence, etc., in which the active ingredient stays on the skin for a long time, contain lower concentrations of acylated saponin than wash-off type cosmetics. It will be okay.

In addition, it may further include adjuvants or carriers, such as stabilizers, solubilizers, vitamins, pigments, or flavorings commonly used in cosmetic compositions or external preparations for skin. Fatty substances, organic solvents, solubilizers, thickeners, gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic emulsifiers, nonionic emulsifiers, fillers, Such as metal ion sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic active agents, lipophilic active agents, cosmetics such as lipid vesicles or any other ingredients commonly used in external preparations for the skin. It may contain adjuvants conventionally used in the field of cosmetics or dermatology. The ingredients may also be introduced in amounts generally used in the cosmetic or dermatological fields.

Acylated saponin according to the present invention shows excellent cyclooxygenase (COX) inhibition and inflammation inhibitory effect, and was very excellent in cytotoxicity and skin safety compared to the existing anti-inflammatory agents.

Advantages and features of the present invention, and methods for achieving them will be apparent with reference to examples and preparations described below in detail. However, the present invention is not limited to the examples and preparations disclosed below, but will be implemented in various different forms, only to make the disclosure of the present invention complete, and having ordinary skill in the art to which the present invention pertains. It is provided to inform the full scope of the invention.

Example 1

Inhibitory effect of cyclooxygenase (Cyclooxygenase, COX)

In the present invention, cyclooxygenase (Cyclooxygenase, COX) was extracted from Pel-Freeze's sheep seminal vesicle (sheep seminal vesicle) was used. Cyclooxygenase according to the present invention (Cyclooxygenase, COX) is the supernatant is taken by centrifugation for 10 minutes at 3000rpm after pulverizing the two hyposperm, the supernatant is centrifuged for 1 hour at 10000rpm to separate the precipitate and Tris buffer It was prepared by dissolving in (0.1M, pH 8.0).

25 μg hemoglobin is added to 100 mL of Tris buffer solution (0.1M, pH 8.0) to make a substrate to 1.1 mM arachidonic acid, and 10 μl of 10,000 units of cyclooxygenase is added to the substrate. Cytoindoside VII, Cytoindoside VIII, and Bellisaponin BA1 were added at 0.5 ppm, 10 ppm, and 50 ppm, respectively, and cyclooxygena was measured by measuring the initial oxygen consumption with a Yellow Spring Instrument company.Model 53 oxygen monitor. The activity was confirmed. The results are shown in Table 1 below.

% Inhibition 0.5 ppm 10 ppm 50 ppm (w / w) Citoinside VII 21 ± 2 34 ± 3 46 ± 4 Cytoinside VIII 24 ± 2 32 ± 4 45 ± 2 Velissaponin BA1 25 ± 2 36 ± 5 42 ± 5

 n = 3

As shown in Table 1, when 50ppm, compared to the negative control group for cyclooxygenase, cytoindoside VII 46%, cytoindoside VIII 45%, Velisaponin BA1 showed an inhibitory effect of 42% Could.

Example 2

Anti-inflammatory effect test

A. Crummey, GP Harper, EA Boyle and FR Mangan.Inhibition of arachidonic acid-induced ear edema as a model for assessing topical anti-inflammatory compound.Agents and Actions 1987: 20: 69 -76) to determine the anti-inflammatory effect.

A total of 56 hairless mice were made of 7 dogs each and 8 sets were made. Both ears of the mouse were thoroughly washed with ethanol, and the thickness was measured using a micrometer. As a control group coated with a sample containing 1 ppm and 10 ppm of cytotoside VII, cytotoside VIII, and velissaponin BA1, a sample containing 1 ppm of indomethacin, and a control group coated with ethanol Divided.

Inflammation was induced by applying 2 mg / ear of arachidonic acid to the right ear of the mouse, and ethanol was applied to the left ear to determine the degree of inflammation caused by the sample itself. One hour later, the sample group contained 1 ppm and 10 ppm of cytosinside VII, cytosineside VIII, and velissaponin BA1, respectively, on both ears coated with ethanol and arachidonic acid, and the comparison group contained 1 ppm of indomethacin. Samples containing the control were applied to both ears of mice continuously for 4 days with 20 μl of ethanol once a day. The degree of edema of both ears was repeated three times for each ear using a micrometer.

The edema inhibition rate of the sample for the control group (ethanol) is shown in Table 2, and the edema inhibition rate for the comparative group (indometacin) is shown in Table 3.

sample density Ear thickness (㎛) % Inhibition Before sample processing After sample processing Sample group Cytoinside VII 1 ppm 322 486 41.6 10 ppm 324 472 50.9 Cito Indian Side Ⅷ 1 ppm 322 497 37.8 10 ppm 323 492 40.0 Velissaponin BA1 1 ppm 321 505 34.5 10 ppm 322 493 38.9 Comparison Indomethacin 1.0 325 452 54.8 Control ethanol 2mg / ear 321 602

※ Inhibition Rate (%) = (AB) / A × 100

   A: average thickness change of control ear

       (Thickness of arachidonic acid-treated ears-thickness of untreated ears)

   B: average thickness change of the sample coated group ears

       (Thickness of sample treated ears-thickness of untreated ears)

% Inhibition compared to the control group (Indometacin) 1 ppm 10 ppm Citoinside VII 75% 93% Cytoinside VIII 69% 73% Velissaponin BA1 63% 71%

As shown in Table 2, at 10 ppm, cytoindoside VII showed 50.9%, cytoindoside VIII showed 40.0%, and velissaponin BA1 had high inhibition rate of 38.9%. In addition, as shown in Table 3, at 10 ppm showed an excellent anti-inflammatory effect of the indomethacin compared to indomethacin VII, 93% of the cytosineside VIII 73%, 71% of the velissaponin BA1.

On the other hand, when the significant difference was verified by edema increase rate, cytoinside VII, cytoinside VIII, and velissaponin BA1 showed an effect of 99% difference with arachidonic acid, respectively.

Example 3

Human patch test for humans

Fifty healthy men and women were subjected to a primary stimulation test in humans according to CTFA guidelines (The Cosmetic, Toiletry and Fragrance Association. Inc. Washington, D.C., 20036, 1991). 50 ppm of cytoinside VII, cytoinside VIII or belisaponin BA1, sample containing 1.0% sodium lauryl sulfate and 10% ethanol, sample containing 1.0% sodium lauryl sulfate and 10% ethanol and ethanol Human irritation was evaluated using 10% as a sample. Each 20 µl of the samples was added dropwise to a Fin chamber, and it was placed on the back of the human body as a test site and fixed with tape. After patching for 24 hours, the patch was then removed. After removing the patch for 4 hours, the skin reaction at the test site was determined according to the following criteria, and the results are shown in Table 4.

    <Judge criteria>

     －: No erythema or unusual phenomenon

      ±: slightly reddish

      +: Significantly redder than the surroundings

    + +: Reddens and swells more heavily than the surroundings

Stimulus = [{(±) Number × 1} + {(+) Number × 2} + {(++) Number × 3}] / Number of Subjects

sample The number of the subjects Judgment result Irritation + + ± － Cytotoside VII (50 ppm),
Sodium lauryl sulfate (1%),
Ethanol (10%) 50 - - 5 45 0.10 Cytotosides shock (50 ppm),
Sodium lauryl sulfate (1%),
Ethanol (10%) 50 - - 4 46 0.08 Velissaponin BA1 (50 ppm),
Sodium lauryl sulfate (1%),
Ethanol (10%) 50 - - 5 45 0.10 Sodium Lauryl Sulfate (1%), Ethanol (10%) 50 2 8 10 30 0.60 Ethanol (10%) 50 - - 10 40 0.20

As can be seen in Table 4, cytoindoside VII, cytoinside VIII and velissaponin BA1 greatly alleviated the stimulation of sodium laurylsulfate and ethanol. This result is thought to be due to the excellent anti-inflammatory effect as shown in the anti-inflammatory effect experiments described above, through which it can be seen that cytoindoside VII, cytoindoside VIII or velissaponin BA1 according to the present invention is a safe ingredient for the skin. Can be.

Example 4

Anti-inflammatory sensory test on human body

Ten subjects of 50 ppm of cytoindoside VII, cytoinside VIII, and velissaponin BA1 were patched twice a day for 7 days to observe the change. Water was used as a control.

Sample (50 ppm) Effective (persons) No change (persons) Citoinside VII 7 3 Cytoinside VIII 8 2 Velissaponin BA1 7 3 water 2 8

As can be seen in Table 5, cytoindoside VII, cytoinside VIII, and velissaponin BA1 effectively alleviated rashes. This result is thought to be due to the excellent anti-inflammatory effect as shown in the anti-inflammatory effect experiments described above, through which it is found that the cytoindoside VII, cytoindoside VIII or velissaponin BA1 according to the present invention is a safe ingredient for the skin Can be.

Hereinafter, the preparation examples (formulation examples) of the cosmetic composition of the present invention are presented, but the following preparation examples are merely illustrative of the compositions of the present invention, but are not limited thereto.

[Production Example 1]

toilet water

Raw material weight% (w / w)

Glycerin 5.0

Dipropylene Glycol 3.0

Hyaluronic Acid 0.5

Polyoxyethylene 0.1

Cured Castor Oil 0.1

Polyethylene Oleylethyl Ethanol 5.0

Preservative 0.15

Spices

Pigment amount

Compound 0.1 of Formula 1

Purified Water to 100

[Production Example 2]

essence

Raw material weight% (w / w)

Cetostearyl Alcohol 1.0

Self-Emulsifying Monostearic Acid 1.0

Beeswax 0.5

Squalane 5.0

Isocetyloctanoate 3.0

Dimethylsiloxane 0.3

Sorbitan monomonate 0.5

Monostearic acid polyethylene glycol 8.0

Glycerin 4.0

Propylene Glycol 0.2

Carboxypolymer 0.22

Triethanolamine 0.25

Preservative

Spices

Pigment amount

Compound of Formula 1 7.0

Purified Water to 100

[Production Example 3]

Lotion

Raw material weight% (w / w)

Cetostearyl Alcohol 0.8

Self-Emulsifying Monostearic Acid 10

Beeswax 0.5

Stearic Acid 0.5

Liquid Paraffin 7.0

Squalane 5.0

Macadamia Oil 3.0

Isocetyloctanoate 2.0

Dimethylsiloxane 0.3

Sorbitan monomonate 0.5

Monostearic acid polyethylene glycol 1.2

Glycerin 4.0

Propylene Glycol 4.0

Betaine 4.0

Carboxypolymer 0.12

Triethanolamine 0.15

Preservative 0.25

Spices

Pigment amount

Compound 5.0 of Formula 1

Purified Water to 100

[Production Example 4]

cream

Raw material weight% (w / w)

Cetostearyl Alcohol 3.0

Self-Emulsifying Monostearic Acid 1.5

Lipophilic Monostearic Acid 1.5

Beeswax 0.5

Liquid Paraffin 8.0

Squalane 7.0

Isocetyloctanoate 4.0

Refined Jojoba Oil 4.0

Dimethylsiloxane 0.3

Sorbitan monosulfate 1.0

Monostearic acid polyethylene glycol 1.2

Glycerin 6.0

Propylene Glycol 4.0

Betaine 4.0

Xanthan Gum 0.06

Triethanolamine 0.10

Preservative 0.25

Spices

Pigment amount

Compound of Formula 1 7.0

Purified Water to 100

Production Example 5

Gel

Raw material weight% (w / w)

Glycerin 4.0

Propylene Glycol 4.0

Ethanol 10

Polyoxyethylene Cured Castor Oil 0.1

Carboxy Polymer 0.30

Triethanolamine 0.30

Preservative

Spices

Pigment amount

Compound of Formula 1 1.0

Purified Water to 100

[Manufacture example 6]

Ointment

Raw material weight% (w / w)

Cetostearyl Alcohol 2.0

Self-Emulsifying Monostearic Acid 2.0

Stearic Acid 1.0

Beeswax 4.0

Squalane 7.0

Monostearineglycerin 3.0

Sorbitan monosulfate 1.0

Polysorbate 80 3.0

Glycerin 5.0

Propylene Glycol 4.0

Spices

Pigment amount

Compound 10.0

Vaseline to 100

Claims (12)

Anti-inflammatory cosmetic composition comprising at least one member selected from the group consisting of cytoindoside VII, cytoindoside VIII, and velissaponin BA1.
The method of claim 1,
The active ingredient is an anti-inflammatory cosmetic composition that is obtained from an extract separated from the plant or synthetic or semisynthetic.
The method of claim 2,
The plant is at least one anti-inflammatory cosmetic composition selected from the group consisting of Winter Cherry (Withania somnifera), Daisy (pellis perennis), Soap bark (Quillaja Saponaria), Albizia adianthifolia and Gleditsia sinensis.
The method of claim 1,
The active ingredient is an anti-inflammatory cosmetic composition comprising 0.001 to 20 parts by weight based on 100 parts by weight of the total cosmetic composition.
The method of claim 1,
The anti-inflammatory cosmetic composition is an anti-inflammatory cosmetic composition having a formulation selected from the group consisting of lotion, milk, cream, essence, spray, gel, pack, sunscreen, makeup base, foundation, powder and detergent.
Anti-inflammatory skin external preparation comprising at least one member selected from the group consisting of cytoindoside VII, cytoindoside VIII, and velissaponin BA1 as an active ingredient.
The method of claim 6,
The active ingredient is an anti-inflammatory skin external preparation that is obtained from a plant isolated extract or synthetic or semi-synthetic.
The method of claim 7, wherein
The plant is one or more anti-inflammatory skin external preparations selected from the group consisting of winter cherries (Withania somnifera), daisies (pellis perennis), soap tree bark (Quillaja Saponaria), albizia adianthifolia and sculpted wood (Gleditsia sinensis).
The method of claim 6,
The active ingredient is an anti-inflammatory skin external preparation is included in an amount of 0.001 to 20 parts by weight based on 100 parts by weight of the total composition.
The method of claim 6,
The skin external preparation is an anti-inflammatory skin external preparation having a formulation selected from the group consisting of ointments, patches, gels, creams and sprays.

delete delete